AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8141715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin with streptokinase (SK)
Number of subjects: 0
Study 8141715 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin with streptokinase (SK)
Number of subjects: 0
Study 8141715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (t-PA)
Number of subjects: 0
Study 2896506 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 2 X 40 mg p.o.
Number of subjects: 20
Study 2896506 — intervention group
Group type: COMPARATOR
Intervention: Betaxolol (Kerlone) 20 mg p.o.
Number of subjects: 20
Study 30320560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-CAS group (300 mg of clopidogrel before stenting)
Number of subjects: 13
Study 30320560 — intervention group
Group type: COMPARATOR
Intervention: Post-CAS group (300 mg of clopidogrel after stenting)
Number of subjects: 13
Study 29928776 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-specified dose of alcohol (0.7 g alcohol/kg body weight)
Number of subjects: 143
Study 26207570 — intervention group
Group type: EXPERIMENTAL
Intervention: Legal prime
Number of subjects: 268
Study 26207570 — intervention group
Group type: COMPARATOR
Intervention: Case vignette alone (Control)
Number of subjects: 268
Study 24660834 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography-guided hemodynamic management (EGHEM)
Number of subjects: 28
Study 24660834 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 28
Study 22119513 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 (0.05 or 0.1 mg)
Number of subjects: 24
Study 22119513 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 24
Study 20096066 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) combined with a bovine-derived xenograft (BDX)
Number of subjects: 24
Study 18844269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 ml of a solution containing 30 units botulinum toxin
Number of subjects: 30
Study 18844269 — intervention group
Group type: COMPARATOR
Intervention: 0.6 ml saline (placebo)
Number of subjects: 30
Study 15031571 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebivolol
Number of subjects: 20
Study 15031571 — intervention group
Group type: COMPARATOR
Intervention: 30 mg nifedipine GITS
Number of subjects: 20
Study 11522047 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg four times daily as a loading dose)
Number of subjects: 9
Study 9735578 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care (MTFC)
Number of subjects: 79
Study 9735578 — intervention group
Group type: COMPARATOR
Intervention: Group Care (GC)
Number of subjects: 79
Study 8296409 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinyl estradiol and 150 micrograms desogestrel (n = 15)
Number of subjects: 34
Study 8296409 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyl estradiol and 75 micrograms gestodene (n = 19)
Number of subjects: 34
Study 2737789 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiDx (720 mg/m2, 60 mg/m2 every 3 weeks)
Number of subjects: 22
Study 2737789 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (Dx) (540 mg/m2, 60 mg/m2 every 3 weeks)
Number of subjects: 22
Study 820882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn
Number of subjects: 17
Study 820882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31977827 — intervention group
Group type: EXPERIMENTAL
Intervention: psychiatry + meditation (n = 8)
Number of subjects: 28
Study 31977827 — intervention group
Group type: COMPARATOR
Intervention: psychiatry only (n = 10)
Number of subjects: 28
Study 31977827 — intervention group
Group type: EXPERIMENTAL
Intervention: meditation only (n = 8)
Number of subjects: 28
Study 30367848 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatrician-performed comprehensive geriatric care
Number of subjects: 368
Study 30367848 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 368
Study 28865981 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 102
Study 28865981 — intervention group
Group type: COMPARATOR
Intervention: Standard Dressing
Number of subjects: 102
Study 26388152 — intervention group
Group type: EXPERIMENTAL
Intervention: Central PET interpretation
Number of subjects: 739
Study 26388152 — intervention group
Group type: COMPARATOR
Intervention: Local PET interpretation
Number of subjects: 739
Study 26388152 — intervention group
Group type: EXPERIMENTAL
Intervention: Central PET review panel
Number of subjects: 739
Study 26388152 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic regime based on central panel decision
Number of subjects: 739
Study 23663109 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy patients
Number of subjects: 288
Study 21874272 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation during the third trimester of pregnancy
Number of subjects: 533
Study 21874272 — intervention group
Group type: COMPARATOR
Intervention: Olive oil supplementation during the third trimester of pregnancy
Number of subjects: 533
Study 21874272 — intervention group
Group type: COMPARATOR
Intervention: No oil supplementation during the third trimester of pregnancy
Number of subjects: 533
Study 19083556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg, twice daily in addition to 5‐mg hydrocodone tablets as needed
Number of subjects: 80
Study 19083556 — intervention group
Group type: COMPARATOR
Intervention: 5‐mg hydrocodone tablets as needed
Number of subjects: 80
Study 16868063 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg, orally, twice a day)
Number of subjects: 76
Study 16868063 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg, orally, twice a day)
Number of subjects: 76
Study 16868063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin and flutamide
Number of subjects: 76
Study 16868063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 12601103 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum PTH group (female stroke patients with serum PTH level higher than mean + 2 SD of control subjects)
Number of subjects: 107
Study 12601103 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal PTH group (female stroke patients with serum PTH level within normal range)
Number of subjects: 107
Study 12601103 — intervention group
Group type: COMPARATOR
Intervention: Control group (107 healthy volunteers matched for age and sex)
Number of subjects: 107
Study 11775043 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 28
Study 11775043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9832970 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125, 0.25, and 0.5 mg/70 kg)
Number of subjects: 11
Study 9832970 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (5, 10, and 20 mg/70 kg)
Number of subjects: 11
Study 8493470 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 0
Study 8493470 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TENS) of the tibial nerve
Number of subjects: 0
Study 8493470 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 3484704 — intervention group
Group type: EXPERIMENTAL
Intervention: St. Thomas Hospital cardioplegia (myocardial temperature below 16 degrees C)
Number of subjects: 72
Study 3484704 — intervention group
Group type: COMPARATOR
Intervention: Intermittent aortic cross‐clamping at 34 degrees C
Number of subjects: 72
Study 3484704 — intervention group
Group type: COMPARATOR
Intervention: Intermittent aortic cross‐clamping at 25 degrees C
Number of subjects: 72
Study 30545995 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-reported all-grade AEs
Number of subjects: 385
Study 30545995 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-reported severity score
Number of subjects: 385
Study 30545995 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of high-grade AEs
Number of subjects: 385
Study 30545995 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported scores
Number of subjects: 385
Study 30545995 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported cumulative toxicity scores
Number of subjects: 385
Study 26791023 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning intervention
Number of subjects: 1158
Study 26791023 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention intervention
Number of subjects: 1158
Study 26791023 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 1158
Study 24769189 — intervention group
Group type: EXPERIMENTAL
Intervention: Attend to Pain
Number of subjects: 62
Study 24769189 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoid Pain
Number of subjects: 62
Study 22791533 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly direct observation with formal feedback (DO-FF)
Number of subjects: 14
Study 22791533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study 20925544 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline (30 mg daily intravenous for up to 3 days)
Number of subjects: 2033
Study 20925544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2033
Study 18194384 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose lenograstim (5 microg per kg once daily)
Number of subjects: 40
Study 18194384 — intervention group
Group type: COMPARATOR
Intervention: Split-dose lenograstim (2.5 microg per kg twice daily)
Number of subjects: 40
Study 15993933 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg/day) for 3 months prior to surgery
Number of subjects: 20
Study 15993933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 12847809 — intervention group
Group type: EXPERIMENTAL
Intervention: Kan-Yang tablets
Number of subjects: 53
Study 12847809 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 53
Study 10228142 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via Turbuhaler (100 microgram per inhalation)
Number of subjects: 22
Study 10228142 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via pMDI (100 microgram per inhalation)
Number of subjects: 22
Study 10228142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10228142 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via either device (pMDI or Turbuhaler)
Number of subjects: 22
Study 10228142 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via pMDI and Turbuhaler
Number of subjects: 22
Study 8568123 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 2.4 mg/day, administered through a pressurized metered-dose inhaler for 4 weeks
Number of subjects: 20
Study 8568123 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as no treatment or placebo during the study)
Number of subjects: 20
Study 1648976 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted platelets plus CMV-seronegative red blood cells
Number of subjects: 77
Study 1648976 — intervention group
Group type: COMPARATOR
Intervention: Standard unscreened blood products
Number of subjects: 77
Study 4043476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined UVB-UVA treatment
Number of subjects: 56
Study 4043476 — intervention group
Group type: COMPARATOR
Intervention: UVB therapy alone
Number of subjects: 56
Study 30225878 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1767
Study 30225878 — intervention group
Group type: COMPARATOR
Intervention: Control (no spironolactone)
Number of subjects: 1767
Study 27710240 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled group (higher P/O)
Number of subjects: 47
Study 27710240 — intervention group
Group type: COMPARATOR
Intervention: Uncoupled group (lower P/O)
Number of subjects: 47
Study 24154932 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily and low-fat diet
Number of subjects: 79
Study 24154932 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet only
Number of subjects: 79
Study 22595156 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial scan protocol
Number of subjects: 400
Study 22595156 — intervention group
Group type: COMPARATOR
Intervention: Helical scan protocol
Number of subjects: 400
Study 20177294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary
Number of subjects: 446
Study 20177294 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 446
Study 20177294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 446
Study 18626299 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE therapy in addition to treatment as usual
Number of subjects: 24
Study 18626299 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy in addition to treatment as usual
Number of subjects: 24
Study 17472487 — intervention group
Group type: EXPERIMENTAL
Intervention: Elixir composed with air-dried C. papaya seeds and honey (CPH)
Number of subjects: 60
Study 17472487 — intervention group
Group type: COMPARATOR
Intervention: Honey alone (placebo)
Number of subjects: 60
Study 14679383 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month isoflavone supplementation (86 mg/day red clover-derived isoflavones)
Number of subjects: 23
Study 14679383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10783653 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized prostaglandin (PG)I2
Number of subjects: 8
Study 10783653 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled NO
Number of subjects: 8
Study 10783653 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PGI2
Number of subjects: 8
Study 10783653 — intervention group
Group type: COMPARATOR
Intervention: Systemic calcium antagonists (CAAs)
Number of subjects: 8
Study 10783653 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term therapy with aerosolized iloprost
Number of subjects: 8
Study 9289326 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 observers (pneumologists) measuring spirometric parameters
Number of subjects: 21
Study 9289326 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 observers (pneumologists) measuring FVC
Number of subjects: 21
Study 9289326 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 observers (pneumologists) measuring FEV1
Number of subjects: 21
Study 9289326 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 observers (pneumologists) measuring FEV1/FVC
Number of subjects: 21
Study 9289326 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardization session for spirometric measurements
Number of subjects: 21
Study 8439095 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid treatment for children with serum FA levels lower than 3 ng/ml
Number of subjects: 110
Study 8439095 — intervention group
Group type: COMPARATOR
Intervention: Anticonvulsant therapy
Number of subjects: 110
Study 8439095 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 110
Study 3531452 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of gentamicin
Number of subjects: 19
Study 3531452 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose therapy of gentamicin
Number of subjects: 19
Study 31960099 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for high hip fracture risk (FRAX)
Number of subjects: 12483
Study 31960099 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 12483
Study 30884079 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-free immunosuppression with everolimus (EVR), mycophenolic acid and steroids
Number of subjects: 145
Study 30884079 — intervention group
Group type: COMPARATOR
Intervention: Reduced-exposure CNI with EVR and steroids
Number of subjects: 145
Study 27859286 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 140
Study 27859286 — intervention group
Group type: COMPARATOR
Intervention: Traditional swallowing exercise (TE)
Number of subjects: 140
Study 25336575 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical brinzolamide (Azopt)
Number of subjects: 5
Study 25336575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 23605805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual 10 mg Promptol™
Number of subjects: 18
Study 23605805 — intervention group
Group type: COMPARATOR
Intervention: Oral Inderal(®)
Number of subjects: 18
Study 23605805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual 40 mg Promptol™
Number of subjects: 18
Study 21698103 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-specific leaflet
Number of subjects: 0
Study 21698103 — intervention group
Group type: COMPARATOR
Intervention: Control leaflet providing information on mental health
Number of subjects: 0
Study 19901236 — intervention group
Group type: EXPERIMENTAL
Intervention: COSA
Number of subjects: 44
Study 19901236 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 44
Study 16290817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy combined with vestibular rehabilitation (VR) program including psychoeducation, vestibular exercises, relaxation, and cognitive interventions.
Number of subjects: 29
Study 16290817 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group.
Number of subjects: 29
Study 12628840 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of CMF treatment
Number of subjects: 204
Study 12628840 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 204
Study 10692092 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with sequential transdermal 17beta‐oestradiol for 14 weeks and then medroxyprogesterone (MPA) for 14 days
Number of subjects: 99
Study 10692092 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 99
Study 9348452 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl‐6‐O‐decanoyl‐glucoside 0.005% combined with 0.00025% chlorhexidine acetate (EDGC)
Number of subjects: 59
Study 9348452 — intervention group
Group type: COMPARATOR
Intervention: Commercial polyaminpropylbiguanide (PAPB)
Number of subjects: 59
Study 8406404 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual morphine sulfate (10 mg)
Number of subjects: 6
Study 8406404 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine sulfate (10 mg)
Number of subjects: 6
Study 8406404 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular morphine sulfate (10 mg)
Number of subjects: 6
Study 3088973 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐alpha‐tocopherol (268 mg)
Number of subjects: 16
Study 3088973 — intervention group
Group type: EXPERIMENTAL
Intervention: DL‐alpha‐tocopherol (364 mg)
Number of subjects: 16
Study 30041978 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Assessment (GA)
Number of subjects: 61
Study 30411137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nationwide skin cancer screening program
Number of subjects: 0
Study 30411137 — intervention group
Group type: COMPARATOR
Intervention: SCREEN project (pilot study)
Number of subjects: 0
Study 30411137 — intervention group
Group type: COMPARATOR
Intervention: Current nationwide skin cancer screening
Number of subjects: 0
Study 27128665 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (EE) at 70% of V˙O2peak
Number of subjects: 9
Study 27128665 — intervention group
Group type: COMPARATOR
Intervention: Blood flow restriction endurance exercise (BFR‐EE) at 40% of V˙O2peak
Number of subjects: 9
Study 27128665 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise at 70% of one-repetition maximum
Number of subjects: 9
Study 24448650 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 17
Study 24448650 — intervention group
Group type: COMPARATOR
Intervention: Continuous aerobic exercise training
Number of subjects: 17
Study 22442962 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypoxant reamberin included in intensive treatment
Number of subjects: 0
Study 20096128 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand sanitisers and an education session on hand hygiene
Number of subjects: 3400
Study 20096128 — intervention group
Group type: COMPARATOR
Intervention: Education session on hand hygiene alone
Number of subjects: 3400
Study 17394707 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue glue (Dermabond, Ethicon, UK)
Number of subjects: 29
Study 17394707 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 29
Study 17394707 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue glue
Number of subjects: 29
Study 16275432 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 182
Study 16275432 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 182
Study 11568553 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg intravenously
Number of subjects: 80
Study 11568553 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study 9676667 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded reviewers (groups 1 and 2)
Number of subjects: 420
Study 9676667 — intervention group
Group type: COMPARATOR
Intervention: Unblinded reviewers (groups 3 and 4)
Number of subjects: 420
Study 9676667 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 5)
Number of subjects: 420
Study 7933233 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management (no treatment)
Number of subjects: 223
Study 7933233 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment (orchiectomy or estrogens)
Number of subjects: 223
Study 7933233 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment and radical prostatectomy
Number of subjects: 223
Study 3283629 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine-mitoxantrone (VM)
Number of subjects: 182
Study 3283629 — intervention group
Group type: COMPARATOR
Intervention: Vindesine-4'-epidoxorubicin (VE)
Number of subjects: 182